Inspiremd Inc (NSPR) Stock Price, Quote & News

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 776 6804

Website: www.inspiremd.com

Address:

6303 Waterford District Drive, Suite 215, Miami, United States

Thespectator Sep. 10 at 2:05 AM

$NSPR you can hardly find a worse performing chart than this, barring muln obviously 😂

0 · Reply

NVDAMillionaire Sep. 9 at 10:34 AM

$NSPR Excellent article that nails exactly where NSPR stands right now. So if you want to update your NSPR knowledge or get acquainted with NSPR, this is a must read. https://beyondspx.com/quote/NSPR/analysis/inspiremd-micronet-technology-poised-for-u-s-market-entry-amidst-liquidity-headwinds-nasdaq-nspr

0 · Reply

Zooooo Sep. 8 at 1:52 PM

$NSPR Not a wrinkle in that 2.4

0 · Reply

LoyalShark Sep. 8 at 11:12 AM

$NSPR Maybe we get lucky today and our current CEO leaves the company. He is the reason the stock sucks. He and he alone. Public market Incompetence on display.

0 · Reply

LoyalShark Sep. 8 at 3:21 AM

$NSPR

0 · Reply

Ronnie5isAlive Sep. 7 at 4:36 PM

$NSPR @LoyalShark is right. After 5 years this stock has been a curse in my life. It has been bringing nothing but bizarre negativity and resentment because of massive opportunity cost. We were blindsided by the toxic financing paired with horrible PR strategy or lack of thereof. It is like a curse and it would be nice to know why the market presence is best described as neglected. At least make an updated youtube promo video that highlights the 2025 Wall street activity, FDA approval and new HQ. This is a perfect example of the status quo. I feel like the low hanging fruit is falling on the ground and rotting. Nobody even wants to talk about this shitty stock anymore because it is shameful to admit you bought it.

0 · Reply

LoyalShark Sep. 7 at 2:58 PM

$NSPR Every single person on this board has been completely wrong so far. There are some smart people on ths board. The question --- WHAT is wrong with our stock? We have NEVER gotten a boost from anything-- NADA. No news stories...no milestones...no confernece calls...no nothing moves this stock. WHAT is wrong with our stock and WHY is InsprieMD doing NOTHING to fix it? Anyone ????

0 · Reply

LoyalShark Sep. 5 at 2:18 PM

$NSPR Anyone have a direct line number to this Webb Campbell guy that shows as the IR guy?

0 · Reply

JBinLB Sep. 4 at 2:06 PM

$DPLS $NSPR Fugayzi, fugazi. It’s a whazy. Its a woozie. Its fairy dust. It doesn’t exist. Its never landed. It is no matter. Its not on the elemental chart. Its not real. Dennis O’B wary

0 · Reply

Zooooo Sep. 4 at 2:03 PM

$NSPR Good morning!

0 · Reply

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 12:30 PM EDT - 5 weeks ago

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 5 weeks ago

InspireMD Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 8:31 AM EDT - 5 weeks ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:30 AM EDT - 5 weeks ago

InspireMD Announces Combined Financings of $58 Million

Jul 22, 2025, 7:00 AM EDT - 7 weeks ago

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 2 months ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 2 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 3 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 3, 2025, 4:05 PM EDT - 3 months ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

May 9, 2025, 12:07 PM EDT - 4 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:00 AM EDT - 4 months ago

InspireMD Reports First Quarter 2025 Financial Results

Apr 30, 2025, 9:00 AM EDT - 4 months ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 25, 2025, 9:00 AM EDT - 4 months ago

InspireMD to Announce First Quarter 2025 Financial Results

Apr 8, 2025, 9:00 AM EDT - 5 months ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 26, 2025, 9:00 AM EDT - 5 months ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 12, 2025, 1:53 PM EDT - 6 months ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 7:00 AM EDT - 6 months ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 6 months ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 7:00 AM EST - 7 months ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Dec 9, 2024, 7:00 AM EST - 9 months ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Nov 25, 2024, 4:05 PM EST - 10 months ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 12, 2024, 10:20 AM EST - 10 months ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Oct 15, 2024, 7:00 AM EDT - 11 months ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 8:09 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 1 year ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Jul 30, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

May 28, 2024, 8:53 AM EDT - 1 year ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

Apr 3, 2024, 8:59 AM EDT - 1 year ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 6, 2024, 11:30 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:00 AM EST - 1 year ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 1 year ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 12, 2024, 7:00 AM EST - 1 year ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Jan 31, 2024, 7:00 AM EST - 1 year ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Jan 3, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Dec 20, 2023, 7:00 AM EST - 1 year ago

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Nov 27, 2023, 7:00 AM EST - 1 year ago

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Nov 6, 2023, 11:09 AM EST - 2 years ago

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 7:00 AM EST - 2 years ago

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 2, 2023, 8:00 AM EDT - 2 years ago

InspireMD to Participate in Upcoming November Investor Conferences

Nov 1, 2023, 2:19 PM EDT - 2 years ago

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

Oct 30, 2023, 9:21 AM EDT - 2 years ago

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

Oct 12, 2023, 7:00 AM EDT - 2 years ago

InspireMD Supports CMS' Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients

Thespectator Sep. 10 at 2:05 AM

$NSPR you can hardly find a worse performing chart than this, barring muln obviously 😂

0 · Reply

NVDAMillionaire Sep. 9 at 10:34 AM

0 · Reply

Zooooo Sep. 8 at 1:52 PM

$NSPR Not a wrinkle in that 2.4

0 · Reply

LoyalShark Sep. 8 at 11:12 AM

$NSPR Maybe we get lucky today and our current CEO leaves the company. He is the reason the stock sucks. He and he alone. Public market Incompetence on display.

0 · Reply

LoyalShark Sep. 8 at 3:21 AM

$NSPR

0 · Reply

Ronnie5isAlive Sep. 7 at 4:36 PM

0 · Reply

LoyalShark Sep. 7 at 2:58 PM

0 · Reply

LoyalShark Sep. 5 at 2:18 PM

$NSPR Anyone have a direct line number to this Webb Campbell guy that shows as the IR guy?

0 · Reply

JBinLB Sep. 4 at 2:06 PM

$DPLS $NSPR Fugayzi, fugazi. It’s a whazy. Its a woozie. Its fairy dust. It doesn’t exist. Its never landed. It is no matter. Its not on the elemental chart. Its not real. Dennis O’B wary

0 · Reply

Zooooo Sep. 4 at 2:03 PM

$NSPR Good morning!

0 · Reply

JBinLB Sep. 4 at 2:02 PM

$NSPR Fugayzi, fugazi. It's a whazy. It's a woozie. It's fairy dust. It doesn't exist. It's never landed. It is no matter. It's not on the elemental chart. It's not real. Do something already you perennial stagnant pond scum

0 · Reply

Ronnie5isAlive Sep. 4 at 3:16 AM

$NSPR today was just another day where this is a bad investment until the day it becomes a good investment.

0 · Reply

HOBOWITHASHOTGUN Sep. 3 at 7:45 PM

$NSPR

0 · Reply

Threeways Sep. 3 at 2:55 PM

$NSPR this is put up of shut up time for Shane Gleason. They hailed him as one of the best at marketing and sales in the business and hired him over (2) years ago for North American sales. If he's unable to sell at least 1,000 stents this quarter then it’s safe to say he’s a major flop of a hire. By my calculation 1,000 stents would be close to $5 million in revenue. Thats a great starting point on sales and definitely a stock moving number!

0 · Reply

Zooooo Sep. 3 at 1:54 PM

$NSPR Good morning

0 · Reply

LoyalShark Sep. 3 at 10:33 AM

$NSPR For YEARS I have been posting CALL THE FUCKEN COMPANY and tell them to get their public market act together. Tell Slosman to get his headout of his ass. AND -- ?????? Nothing. EVERYTHING Slosman has done and not done is why we sit here in a fn POS stock while the rest of the market explodes. The guy is a disaster - absolute disaster in the public markets.

1 · Reply

Ronnie5isAlive Sep. 3 at 3:42 AM

$NSPR owning this stock had been so stressful I had to get a head tumor removed. I added the co payments to my cost basis adding around .30 a share.

1 · Reply

jensen146 Sep. 2 at 7:57 PM

$NSPR Why don't we ever hear about any big sales. If you are getting big VA or HHS contracts maybe we should hear about it. Are the big insurers authorizing reimbursement. Maybe your so busy taking orders you don't have time.

0 · Reply

HOBOWITHASHOTGUN Sep. 2 at 1:49 PM

$NSPR We need to wake up here...

0 · Reply

LoyalShark Sep. 2 at 10:20 AM

$NSPR Pathetic in nearly every way. You want the life drained out of you --- just buy a few shares. Maybe its the 2% yr over yr global growth or the perpetual dilution. Or the cash burn rate. IDK.

0 · Reply

Zooooo Aug. 29 at 8:12 PM

$NSPR Just a little flat into next week

0 · Reply

Zooooo Aug. 29 at 12:02 AM

$NSPR Gotta be patient

1 · Reply

Market Cap	100.13M
Revenue (ttm)	7.01M
Net Income (ttm)	-32.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-456.63%
Debt to Equity Ratio	0.00

Volume	52,700
Avg Vol	99,156
Day's Range	N/A - N/A
Shares Out	41.72M
Stochastic %K	69%
Beta	0.68
Analysts	Strong Sell
Price Target	$4.50